Renewal for Vor via PIPE, licensing deal: Public Equity Report

Vor Bio’s decision last month to explore strategic options has resulted in a company makeover, as the company has taken most global rights to an immunology program, introduced a new CEO and drawn $175 million in fresh funding.

Once focused on cell therapies for hematological cancers, Vor Biopharma Inc. (NASDAQ:VOR) has now taken worldwide, ex-Greater China rights to telitacicept, a fusion protein targeting BAFF and APRIL, in a deal with Remegen Co. Ltd. (HKEX:9995; Shanghai:688331). Vor will pay Remegen $125 million, comprising a $45 million upfront payment, plus $80 million in equity via the sale of 320 million prefunded warrants...